A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer.

ABSTRACT:

Background

Small cell lung cancer (SCLC) is known for its highly invasive nature and low 5-year survival rate. Although immunotherapy has shown enhancements in survival among SCLC patients, there is a call for improved precision in targeting beneficiary populations. The development of the Delta-like ligand 3 (DLL3)-targeted drug Rovalpituzumab Tesirine (Rova-T) was halted due to insufficient efficacy, prompting a closer examination of factors influencing treatment effectiveness. This study aims to create a prognostic model for SCLC patients based on protein expression levels to enhance prognosis determination and guide clinical decision-making.

Methods

Immunohistochemistry assessed DLL3, Programmed death-ligand 1 (PD-L1), and c-kit expression in SCLC patients. Univariate and

SUBMITTER: Zhang X 

PROVIDER: S-EPMC12673796 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature